AbbVie Inc

The Trump administration has selected 10 companies, including AbbVie, Amgen, Pfizer, and GSK, for a new pilot program that tests a rebate model for drugs purchased under a federal program benefiting uninsured and low-income patients. The 340B Rebate Model Pilot takes effect on January 1 and allows the selected manufacturers to verify and pay rebates for 21 discounted drugs purchased under the government's 340B drug pricing program, rather than offering savings upfront as under the current discount model. The participating drugmakers are AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers, GSK, Merck, Pfizer, and Teva. The Health Resources and Services Administration, the HHS unit overseeing the program, said the approach helps address compliance concerns proactively rather than relying primarily on retrospective reviews, audits, and dispute resolution processes. The pilot marks the Trump administration's second attempt to overhaul the decades-old drug discount program, after a federal judge blocked HRSA's first 340B rebate pilot following a case brought by hospital groups last year.

AbbVie reported late-breaking Phase 3 data showing that RINVOQ (upadacitinib) 15 mg once daily produced continued facial and total body repigmentation in non-segmental vitiligo through week 76. In the ongoing Viti-Up-1 and Viti-Up-2 studies, patients who continued RINVOQ in the open-label extension saw F-VASI 75 response rates rise from 33.1% at week 48 to 55.1% at week 76 in Viti-Up-1 and from 27.6% to 47.4% in Viti-Up-2, while T-VASI 50 rates increased from 29.2% to 42.5% and from 26.2% to 40.1%, respectively. A phototherapy substudy of 84 adults who failed to achieve T-VASI 90 at week 48 found numerically higher responses with RINVOQ plus whole-body narrowband ultraviolet B phototherapy than with RINVOQ alone, with F-VASI 75 of 59.3% versus 37.0% and T-VASI 50 of 63.0% versus 33.3% at week 28 in patients who had received RINVOQ in Period A. Safety results through week 76 and week 28 were consistent with the known profile of upadacitinib, with no new safety signals. RINVOQ is the first and only systemic medication approved in the European Union for non-segmental vitiligo in patients 12 years and older who are candidates for systemic therapy, and its use in the condition is under regulatory review by the U.S. FDA.

AbbVie reported Phase 2 APEX Part B data for zumilokibart in moderate to severe atopic dermatitis at the EADV Congress, and selected a mid dose of the drug for Phase 3 development after the study showed significant clinical improvements in patients. The company also joined the Antibody Developability Consortium as a founding member and started a new AI driven R&D collaboration with Valkai. The zumilokibart Phase 2 results and the new AI alliances feed into AbbVie's core research and development engine as it works to replace aging blockbusters with new immunology and neuroscience drugs alongside Skyrizi, Rinvoq, Vraylar and Vyalev. The next test is whether AbbVie converts the announcements into hard pipeline milestones, with investors watching for the full APEX Part B dataset and Phase 3 trial design updates for zumilokibart after EADV 2026, along with any 2027 commentary on AI enabled cycle time or cost savings in R&D.

AbbVie presented detailed Phase 1 data at the European Association for the Study of Diabetes 2026 Annual Meeting in Milan showing that its investigational long-acting amylin analog ABBV-295 achieved an approximately 11- to 12-day half-life and dose-proportional increases in plasma exposure, supporting evaluation of dosing intervals beyond weekly administration, including every-other-week and monthly regimens. The results come from the 60 participants in Part 2B/2C of the multiple ascending dose study, who were randomized to receive ABBV-295 (n = 45) or placebo (n = 15), with a mean age of 41.5 years, a mean BMI of 29.3 kg/m2, and 88% male participants. ABBV-295 was dose-escalated to 4, 6, or 14 mg once weekly, 14 mg every other week, or 8 mg monthly, and administered for 12 or 13 weeks. Least-squares mean body weight reductions ranged from -7.8% to -9.8% at Week 12 for the once-weekly dosing cohorts and were -9.7% for the every-other-week cohort and -7.9% for the monthly cohort at Week 13, compared with approximately -0.3% for placebo. Gastrointestinal adverse events were predominantly mild and occurred primarily during the first six weeks of treatment, with nausea reported in 33.3% of participants receiving ABBV-295 versus 20.0% receiving placebo and diarrhea in 20.0% versus 0.0%; no severe GI adverse events or serious treatment-emergent adverse events were reported. AbbVie said the findings support advancing ABBV-295, a non-incretin amylin-based mechanism, into Phase 2 development for chronic weight management.

AbbVie secured FDA approval for Juvmo, a once-daily Parkinson's treatment, though its shares slipped nearly 0.8% to $264.29. Juvmo works through D1/D5 dopamine receptors, a different target from older dopamine agonists. In the TEMPO-3 trial, patients taking it alongside levodopa gained 1.7 hours a day with symptoms controlled and no troublesome involuntary movement, compared with 0.6 hours for those given a placebo. AbbVie expects U.S. availability in October but has not disclosed Juvmo's price or a sales forecast, and nausea, dizziness and hallucinations are among the treatment concerns physicians must weigh. At $264.29, the stock sits 19.43% above its $221.28 GF Value estimate.

AbbVie announced that the FDA has approved tavapadon, to be marketed as Juvmo, as a once-daily oral treatment for Parkinson's disease, with a commercial launch set for next month. The company said the approval marks the first dopaminergic breakthrough for Parkinson's in decades, and Juvmo can be used alone or in combination with levodopa, the current standard of care. Juvmo is the first selective D1/D5 dopamine receptor agonist approved for Parkinson's disease, and the FDA decision was supported by three late-stage studies, TEMPO-1, TEMPO-2 and TEMPO-3, which showed symptomatic improvement across a broad patient population. AbbVie gained the drug through its approximately $8.7 billion acquisition of Cerevel Therapeutics, completed in 2024. The approval expands AbbVie's Parkinson's portfolio, which previously included Vyalev and Duopa, and management expects the three therapies to collectively represent a Parkinson's opportunity of more than $5 billion in peak sales.

AbbVie is investing in its artificial intelligence infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches patients. Under the collaboration, AbbVie will deploy purpose-built AI capabilities across targeted areas of clinical research to improve efficiency, help teams generate insights more quickly and support opportunities to reduce development timelines. Nicholas Donoghoe, executive vice president and chief business and strategy officer at AbbVie, said that as clinical data grows in volume and complexity, the partnership helps the company generate insights faster and lets teams spend more time on the decisions that matter most. Andrew Campbell, M.D., vice president of clinical sciences at AbbVie, said AI capabilities like Valkai have the potential to reduce time spent on manual processes and focus more attention on scientific interpretation and clinical strategy. Valkai, which describes itself as the AI operating system for life sciences, said its team hails from companies including OpenAI, Google DeepMind, Sierra and Glean, and that global Fortune 500 pharma and medtech leaders partner with it for faster, smarter decision-making.

Ginkgo Datapoints, an offering of Ginkgo Bioworks, and Apheris GmbH announced that the Antibody Developability Consortium has launched with AbbVie, argenx, Lundbeck, and Takeda as founding members. The industry collaboration aims to build the field's largest standardized antibody developability dataset, with each founding member contributing proprietary antibody sequences and Ginkgo Datapoints filling any remaining capacity from publicly available sources to reach 10,000 antibodies in total. Using Apheris' federated infrastructure, members can train, benchmark, and refine AI models on the full consortium dataset without exposing their raw proprietary sequences to other members, and they retain ownership of the sequences and assay data they contribute. Ginkgo Datapoints leads the scientific design and execution, including sequence selection, antibody production, and high-throughput wet-lab characterization, and trains a foundation antibody developability model within Apheris' secure environment. Charlotte Deane of the University of Oxford and Peter Tessier of the University of Michigan will provide independent scientific oversight, and the consortium's initial dataset is targeted for delivery to members by early 2027.

ADARx Pharmaceuticals is seeking a valuation of as much as $1.74 billion in a US IPO that could raise up to $371.9 million. The San Diego-based RNA drug developer plans to offer 21.9 million shares at between $15 and $17 apiece and list on the Nasdaq under the ticker ADRX. AbbVie has agreed to invest up to $100 million through a concurrent private placement, which ADARx said would give AbbVie a roughly 4.9% stake following the IPO; AbbVie had previously paid ADARx $335 million in May 2025 as part of a research collaboration. Three of ADARx's experimental drugs are in clinical testing and another two are in advanced preclinical development, with its most advanced candidate, onvuzosiran, in late-stage testing for hereditary angioedema. IPOX Research Associate Lukas Muehlbauer described the AbbVie investment as external validation of ADARx's technology, though the valuation still rests on experimental medicines with no approved product.

AbbVie Inc. and Iambic announced a multi-year collaboration to use Iambic's AI platform to accelerate small-molecule drug discovery across immunology, neuroscience, and oncology. The partnership will use Iambic's Enchant v3 model, which is trained on more than 6,000 molecular properties and is designed to evaluate multiple drug characteristics simultaneously, with the companies pursuing candidates with first-in-class and best-in-class potential. Iambic will receive an upfront payment, milestone payments, and tiered royalties on net sales, though the financial terms were not disclosed. The deal comes as AbbVie leans on newer products to offset Humira's decline: in the first half of 2026, Skyrizi generated $9.99 billion, up 27.3%, and Rinvoq generated $4.64 billion, up 24.0%, while Humira revenue fell 37.3% to $1.44 billion, and Vraylar revenue rose 18.7% to $1.98 billion. AbbVie's second-quarter 2026 revenue reached $16.99 billion, up 10.2%, with Skyrizi and Rinvoq together generating $8.03 billion, up roughly 24% year over year, and its 2025 filing says U.S. composition-of-matter patents for Skyrizi and Rinvoq are expected to expire in 2033. The collaboration carries no immediate earnings catalyst, since any royalties or product revenue depend on successful discovery, clinical development, and regulatory approval, and AbbVie would share economics through milestone payments and tiered royalties if Iambic's models produce successful medicines.

AbbVie acquired a stake in ADARx Pharmaceuticals during its IPO, gaining exposure to RNA interference drug candidates being developed for certain rare disease indications. Separately, Health Canada granted marketing authorization for AbbVie's EPKINLY for adults with relapsed or refractory follicular lymphoma. The ADARx investment signals that AbbVie is still willing to write cheques to secure optionality in newer modalities like RNA interference rather than relying only on in-house discovery, while the EPKINLY approval pushes the oncology franchise further into later-line hematology care. Both moves feed into AbbVie's broader effort to replace revenue from declining products such as Humira and Imbruvica, though analysts have flagged the company's continued concentration in a small cluster of major therapies as a risk around patent cliffs and pricing pressure.

REGENXBIO Inc. announced positive three-year long-term follow-up data from the Phase II ALTITUDE study of investigational surabgene lomparvovec, also known as sura-vec or ABBV-RGX-314, in non-proliferative diabetic retinopathy using suprachoroidal delivery, presented at the Retina Society 59th Annual Scientific Meeting in Los Angeles. In data as of August 17, 2026, 60% of all Dose Level 3 participants with three-year visits, or 6 of 10, achieved a greater than 2-step improvement on the Diabetic Retinopathy Severity Scale without additional treatment for diabetic retinopathy, and these participants experienced no vision-threatening events. Additionally, the majority of participants, 3 of 4, who achieved a 1-step DRSS improvement at one year without supplemental anti-VEGF injections went on to achieve a greater than 2-step DRSS improvement by three years without additional treatment. No new sura-vec-related safety signals and no intraocular inflammation were observed through three years in 17 participants receiving short-course prophylactic topical steroids. Dose Level 3 is being evaluated in the Phase IIb/III NAAVIGATE trial of sura-vec in NPDR, and REGENXBIO is developing sura-vec in collaboration with AbbVie.

AbbVie announced that Health Canada has issued a Notice of Compliance for EPKINLY, also known as epcoritamab, for a new follicular lymphoma indication in adults. The approval covers EPKINLY in combination with lenalidomide and rituximab for adult patients with relapsed or refractory Grade 1, 2, or 3a follicular lymphoma who have received at least one prior line of systemic therapy. The authorization is supported by results from the Phase 3 EPCORE FL-1 study, which included 488 adults with relapsed or refractory follicular lymphoma, in which adding EPKINLY to lenalidomide and rituximab reduced the risk of disease progression or death by 79% compared with lenalidomide and rituximab alone, with a hazard ratio of 0.21 and a 95% confidence interval of 0.13 to 0.33 and a p value below 0.0001. EPKINLY is a bispecific antibody administered by injection under the skin and is being co-developed by AbbVie and Genmab as part of the companies' oncology collaboration. Follicular lymphoma is the second most common subtype of non-Hodgkin lymphoma, accounting for approximately 20% to 25% of NHL diagnoses in Canada, with approximately 2,400 to 3,000 Canadians diagnosed each year.

Iambic Therapeutics filed for a U.S. IPO on September 21 after raising money from NVIDIA Corporation and Qatar Investment Authority, and the same day announced a multi-year research collaboration with AbbVie Inc. Under the agreement, AbbVie can use Iambic's Enchant platform to design small-molecule programs across immunology, neuroscience and oncology, with the deal including a $40 million upfront payment, up to $670 million in development and sales-based milestones across the two collaboration targets, and tiered royalties ranging from the mid-single digits to the low teens. AbbVie entered the collaboration from a position of operating strength, with Q2 2026 revenue of about $16.99 billion as Skyrizi and Rinvoq helped offset legacy Humira erosion. NVIDIA, meanwhile, stands to benefit as drug-design startups consume accelerated compute for training, simulation and inference, though even a successful biotech investment is tiny relative to its data-center business. The IPO will expose investors to the riskiest layer of the AI drug discovery value chain directly, while ABBV and NVDA offer more diversified ways to watch the same thesis.

AbbVie received European Commission approval for RINVOQ in polyarticular juvenile idiopathic arthritis for patients as young as two. The company also launched AA Signature SKIN360 in the U.S. through Allergan Aesthetics, a multimodal digital platform for medical aesthetics consultations, and entered AI-focused collaborations with Iambic and the AISB Bind project to apply advanced models to drug discovery and molecular binding prediction. AbbVie, a research-focused biopharmaceutical group with a market value of about $467.4b, is using these moves to extend from core medicine development into digital tools and patient-facing services. The RINVOQ pediatric extension, the AA Signature SKIN360 rollout and the new AI partnerships are only part of AbbVie's broader story, with the company pointing to diversified growth beyond Humira. Follow-through markers include RINVOQ uptake in European pediatric arthritis treatment data, early output from the Iambic and AISB Bind collaborations such as disclosed preclinical candidates, and digital aesthetics usage updates when AbbVie next reports segment performance or holds its 2027 guidance discussions.

AbbVie reported second-quarter revenues of $16.99 billion, up 10.2% year on year and 1.2% above analysts' consensus expectations, though the quarter was mixed with only a narrow beat of EPS estimates and a slight miss of full-year EPS guidance estimates. The results came as the 11 therapeutics stocks tracked by the report collectively beat consensus revenue estimates by 8% in Q2, with share prices up 24.8% on average since the latest earnings results. Biogen posted the group's best quarter, with revenues of $2.74 billion, up 3.4% year on year and 12.1% above expectations, while Myriad Genetics delivered the weakest performance, reporting revenues of $190.7 million, down 10.5% year on year and 8.2% below expectations, alongside full-year revenue guidance that missed and a significant EPS miss. Gilead Sciences reported revenues of $7.80 billion, up 10.2% year on year and 6.2% above expectations, and Moderna reported revenues of $145 million, up 2.1% year on year and 35.8% above expectations, the biggest analyst estimate beat of the group. AbbVie's stock is up 2.9% since reporting and currently trades at $264.79.

The AI Structural Biology Network, powered by Apheris, launched AISB Bind, a federated initiative in which AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson will collaboratively train an AI model to predict how small molecules bind to protein targets for virtual screening and lead optimization. The new initiative extends the network's first effort, which focused on protein-ligand structure prediction, where a co-folding model fine-tuned across more than 20,000 proprietary structures from active drug-discovery programs raised the share of high-quality predictions from 36% to 52%, outperforming public models and any model fine-tuned on a single partner's data alone. In AISB Bind, the four founding partners contribute three complementary types of data: experimentally determined structures, quantitative affinity and potency measurements, and high-throughput screening activity data, the last adding a large body of confirmed non-binders that is rarely available at industrial scale. Training runs through federated learning, so each partner's proprietary data stays within its own secure environment, with Apheris hosting the network and running the training and each partner receiving the resulting model to run and further tailor internally. Federated training begins in September 2026, with final models expected in early 2027, powered by the infrastructure of Apheris's technology partner, Amazon Web Services.

AbbVie announced top-line results from a Phase 3 clinical trial showing its migraine treatment Qulipta significantly reduced migraine days versus placebo during the perimenstrual period in patients with menstrual migraine, the study's primary endpoint, while also meeting all secondary endpoints with no new safety signals. Qulipta, first approved in the U.S. in 2021 for migraine prevention and later expanded to chronic migraine in adults, could become the first medicine approved specifically for menstrual migraine, a niche with no approved treatments; AbbVie estimates a potential U.S. market of more than nine million adult patients in this indication. In the second quarter, Qulipta posted $350 million in sales, up 31% year over year, and some analysts expect peak sales of over $2 billion, against $1 billion in revenue last year, though AbbVie's total second-quarter revenue grew 10% year over year to $17 billion. AbbVie's larger growth drivers remain the immunology drugs Skyrizi and Rinvoq, which management expects to generate more than $31 billion in combined revenue this year, a milestone originally forecast for 2027 and raised by $4 billion from an earlier projection. The company also recently closed its $10.9 billion acquisition of Apogee Therapeutics, gaining zumilokibart, a late-stage immunology asset that some analysts say could reach $5.2 billion in peak eczema sales alone.

AbbVie shared new real-world and pediatric safety data for VRAYLAR in major depressive disorder and bipolar I at Psych Congress 2026. The findings covered routine clinical practice settings, including patients with complex comorbidities and underserved groups, while the pediatric data added information on safety and use in younger patients with mood disorders. AbbVie, a research-focused biopharmaceutical group with a US$466.6b market cap, positions VRAYLAR within a broad portfolio targeting chronic conditions including complex psychiatric disorders. The company said the next concrete checkpoint will be how these data feed into prescribing and label use over the next year, particularly uptake of newly approved low dose VRAYLAR in pediatric and adjunctive MDD settings, trackable in reported prescription trends and segment sales through 2027.

AbbVie Inc. has declared another quarterly dividend of $1.73 per share, payable November 16, 2026, to shareholders of record as of October 15, holding the payout steady throughout 2026 after raising it from $1.64 earlier in the year. The $1.73 quarterly payment works out to $6.92 per share annually and a yield of roughly 2.7%, a moderate level that AbbVie has not raised again this year. The company's dividend growth record is the larger story: the quarterly payout has climbed from $1.41 in 2022 to $1.48 in 2023, $1.55 in 2024, $1.64 in 2025 and $1.73 in 2026, a roughly 23% increase over that span, and AbbVie has raised its quarterly dividend by more than 330% since it was established in 2013, with the latest increase at 5.5%. In its latest SEC filing, AbbVie reported $7.27 billion in operating cash flow for the first six months of 2026, up from $6.79 billion a year earlier, while paying $6.2 billion in cash dividends during the same period, and it spent about $1.1 billion on acquisitions and investments and another $1.1 billion on share repurchases in that half. AbbVie said future dividends remain subject to board approval and cited its financial condition, capital requirements and debt obligations as factors.

AbbVie announced that full results from the Phase 3 CERVINO study of its investigational drug etentamig will be featured in a plenary presentation at the 23rd International Myeloma Society Annual Meeting, held September 23-26, 2026, in Glasgow, Scotland. Topline results showed that etentamig, a second-generation BCMA x CD3 bispecific T-cell engager, met the study's dual primary endpoints of objective response rate and progression-free survival versus standard available therapies in adults with triple-class exposed relapsed/refractory multiple myeloma. Beyond CERVINO, AbbVie will present research spanning its myeloma pipeline, including ABBV-2001 (ISB 2001), a CD38 x BCMA x CD3 trispecific T-cell engager, and surzetoclax, a BCL-2 small-molecule inhibitor, alongside studies of etentamig across multiple treatment settings. Additional presentations will cover treatment sequencing, infection-related healthcare utilization and costs, and real-world outcomes. Etentamig, ABBV-2001 (ISB 2001) and surzetoclax are investigational medicines and are not approved by any health authorities worldwide.

Allergan Aesthetics, an AbbVie company, announced results from two single-center clinical studies evaluating targeted skincare regimens alone and in combination with DiamondGlow dermabrasion treatments in individuals taking medical weight loss medications, including glucagon-like peptide-1 receptor agonists. The studies, presented at the Science of Skin Summit in Austin, Texas, from Sept. 17-20, 2026, showed statistically significant, investigator-assessed improvements in selected skin quality measures across the face, neck, upper inner arms and distal thighs. The 12-week skincare study included nine participants who completed the study, while the six-week DiamondGlow plus skincare study included 11 participants who completed at least one post-treatment assessment. In the 12-week study, participants reported that facial skin appeared approximately 10 years younger after four weeks of twice-daily growth factor serum use, and in the six-week study, participants reported facial skin appeared approximately 7.5 years younger after three DiamondGlow treatments and six weeks of the topical skincare regimen. Elizabeth Makino, a co-author of both studies and director of clinical development and global scientific affairs for skincare research and development at Allergan Aesthetics, said the early data contribute clinical evidence evaluating these approaches and that additional research in larger populations will help further characterize the findings.

AbbVie has raised its full-year 2026 neuroscience revenue outlook to approximately $12.7 billion, $100 million above its previous forecast, after the franchise generated $6.1 billion in first-half 2026 revenues, up 21.8% year over year on an operational basis. The growth was broad-based across the portfolio's three pillars of psychiatry, migraine and Parkinson's disease. Vraylar, the cornerstone of the psychiatry franchise, generated $1.98 billion in the first half, up 18.6%, and is now expected to approach $4.1 billion in full-year sales, while Botox Therapeutic brought in $2.05 billion and is expected to reach nearly $4.2 billion. In migraine, Ubrelvy generated $731 million and Qulipta $646 million, with Qulipta leading growth at 39.2% and Ubrelvy at 26.4%. The Parkinson's therapy Vyalev generated $457 million in first-half sales, with second-quarter sales up more than 27% sequentially, and AbbVie said it is well on track to achieve blockbuster sales this year. AbbVie also raised its overall 2026 revenue outlook by $300 million to approximately $67.6 billion, and expects an FDA decision on tavapadon, a once-daily oral Parkinson's therapy, in the third quarter of 2026, with management projecting more than $5 billion in peak sales across its three Parkinson's therapies.

Zelgen Pharmaceuticals Executive Vice President and Chief Scientific Officer Lyu Binhua revealed that the company has entered into a strategic partnership with multinational pharmaceutical company AbbVie regarding overseas licensing of its products. Lyu made the remarks while appearing on the first episode of the third season of the program "Hardcore Players in the Shanghai Market," themed "Innovative Drugs Crossing the Value Inflection Point." In 2025, Zelgen Pharmaceuticals reported revenue of 810 million yuan, up 52 percent year on year. In the first half of 2026, the company's revenue reached 1.205 billion yuan, achieving its first-ever half-year profit.

AbbVie Inc. said its migraine treatment atogepant, sold as Qulipta in the U.S., met the main goal of a late-stage study evaluating its ability to prevent migraines associated with the menstrual period. Patients taking the drug experienced an average of 0.8 fewer migraine days than those receiving placebo over three menstrual cycles, with the treatment taken for seven consecutive days around the expected start of menstruation. Because atogepant is already approved in the U.S. for migraine prevention, the new data could potentially support an additional indication without requiring AbbVie to establish an entirely new drug franchise. The company may still need to show a meaningful advantage for menstrual migraine patients, since the benefit was modest and competition remains intense from rivals including Eli Lilly and Pfizer. The new indication could also have a limited incremental revenue impact, as menstrual migraine represents a narrower patient population than the broader migraine-prevention market.

AbbVie said its migraine drug Qulipta achieved the main goal of a Phase 3 trial targeting menstrual migraine, sending shares up about 0.4% to $252.25 Thursday morning. The trial tested a sharper, more targeted dosing schedule, giving patients atogepant for seven straight days starting three days before menstruation across three cycles. Qulipta reduced perimenstrual migraine days by 0.8 versus placebo while also improving headache burden, rescue-medication use, disability and cognitive symptoms. Commercially, Qulipta delivered $350 million in second-quarter revenue, rising 30.9% and accounting for roughly 10.8% of AbbVie's $3.23 billion neuroscience portfolio. The $252.25 share price stands 14.55% above the $220.20 GF Value estimate, and detailed safety results, regulatory approval and insurer coverage still separate positive data from new revenue.

AbbVie's immunology franchise generated $16.1 billion in first-half 2026 sales, more than half of the company's total sales, as Skyrizi and Rinvoq continued to offset the biosimilar erosion of Humira that began in the United States in 2023. The segment's sales rose nearly 16% year over year on a reported basis, outpacing AbbVie's overall revenue growth, and the company expects combined Skyrizi and Rinvoq sales to exceed $31 billion in 2026. Rinvoq was approved in the EU in July for vitiligo and alopecia areata, and AbbVie believes those two indications alone can add up to $2 billion in combined peak sales, while phase III data for Rinvoq in hidradenitis suppurativa and systemic lupus erythematosus are expected later this year. Supported by those two drugs, AbbVie expects high-single-digit compound annual revenue growth through 2029, with no major loss-of-exclusivity events expected to materially disrupt the business through the rest of the decade. Beyond its current leaders, AbbVie is evaluating Skyrizi-based combination regimens with ABBV-382 and ABBV-701 in inflammatory bowel disease, seeking approval for a subcutaneous induction regimen of Skyrizi in Crohn's disease, and has added pipeline assets through acquisitions including Nimble Therapeutics, Capstan Therapeutics and Apogee Therapeutics, whose zumilokibart is a phase III-ready long-acting anti-IL-13 antibody for atopic dermatitis that AbbVie believes can compete with Dupixent.

AbbVie Inc. finalized its acquisition of clinical-stage biotech Apogee Therapeutics for $135.11 per share in cash, a $10.9 billion deal that folds Apogee's inflammatory and immunology pipeline into AbbVie's commercial engine. On the same day, AbbVie reported positive Phase 3 results for its bispecific T-cell engager etentamig in relapsed/refractory multiple myeloma, highlighting the company's push into next-generation immunology and oncology. In Q2 2026, AbbVie posted $16.99 billion in net revenue, up 10.2% year over year, with adjusted diluted EPS rising 22.9% to $3.65, driven by immunology blockbusters Skyrizi and Rinvoq, which grew 24.4% and 24.5% respectively, offsetting a 35.9% decline in Humira revenue. AbbVie reiterated its full-year 2026 adjusted EPS guidance of $13.87–$14.07, including a $0.14 dilutive impact from the Apogee transaction. Apogee, which generated no product revenue in Q2 2026, reported a net loss of $85.9 million but held $1.3 billion in cash and marketable securities, plus a $1.3 billion non-dilutive credit collaboration with Blackstone Life Sciences to support Phase 3 trials of its lead asset zumilokibart. Investors should watch full plenary data for etentamig at the International Myeloma Society Meeting from September 23–26 and monitor Phase 3 execution for zumilokibart under AbbVie's global structure.

AbbVie announced positive top-line results from the Phase III CERVINO study, in which its investigational drug etentamig significantly improved objective response rate and progression-free survival compared with standard therapies in patients with relapsed or refractory multiple myeloma who had been exposed to three major drug classes. The study met both primary goals, with etentamig achieving an objective response rate of 74% versus 45.7% for standard available therapies, and reducing the risk of disease progression or death by 60%, corresponding to a progression-free survival hazard ratio of 0.40. At 12 months, the overall survival rate was 87.9% for etentamig-treated patients versus 72% for those on standard therapies, though the prespecified statistical boundary for overall survival was not crossed at the data cutoff. The drug also showed a manageable safety profile with low rates of cytokine release syndrome and fatal infections. AbbVie plans to discuss the results with regulatory authorities and present the data at a medical conference later this month. Separately, AbbVie completed its acquisition of Apogee Therapeutics for approximately $10.9 billion, strengthening its immunology pipeline with dermatology, respiratory, and inflammatory disease assets.

Allergan Aesthetics, an AbbVie company, has expanded its SkinMedica portfolio with the launch of Barrier Calming Cream, a restorative moisturizer designed to soothe skin and fortify the skin barrier, alongside the new HA5 Hydra Collagen Facial Mist with Vegan Collagen. In clinical testing, the cream improved skin barrier support and reduced skin dryness by 30% after just two weeks, while the mist immediately increased skin hydration by 31% with one application and improved dryness by 62%. The products are priced at $140 and $58 respectively and are available at SkinMedica.com and through licensed physicians and medically supervised spas. Nicole Mowad-Nassar, president of Global Allergan Aesthetics, highlighted the brand's pioneering role in regenerative skincare, and Prithwiraj Maitra, vice president of global skincare R&D, noted the cream's clinically proven ability to restore the barrier and support retinol tolerance.

AbbVie has submitted a regulatory application to the European Medicines Agency seeking approval for its blockbuster immunology drug Skyrizi (risankizumab) as a subcutaneous induction treatment for adults with moderately to severely active Crohn's disease. If approved, EU patients would gain an additional subcutaneous induction option alongside the currently approved intravenous regimen, followed by maintenance dosing every eight weeks. The filing is based on data from the phase III AFFIRM study, which evaluated the drug's safety and efficacy in this patient population, including those with and without prior advanced therapy failure. AbbVie is also awaiting a U.S. regulatory decision on the same regimen, expected in the fall, which could improve convenience and competitive positioning. Skyrizi sales rose 26.3% year over year to nearly $10 billion in the first half of 2026, accounting for about 31% of AbbVie's total revenues, though the company faces pricing headwinds and competition from J&J's new oral pill Icotyde and Eli Lilly's Omvoh.

AbbVie presented new clinical, translational and real-world data from its lung cancer portfolio at the World Conference on Lung Cancer in August 2026, including high objective response rates and generally manageable safety profiles for investigational therapies ABBV-1480 and ABBV-706, plus progress on Temab-A trials in non-small cell lung cancer. The breadth of these lung cancer programs, spanning bispecific antibodies and antibody-drug conjugates across first-line and relapsed settings, underscores how oncology innovation is becoming a more important pillar alongside AbbVie's existing immunology and neuroscience franchises. The company's narrative projects $81.5 billion revenue and $24.6 billion earnings by 2029, requiring 8.2% yearly revenue growth and about an $18.3 billion earnings increase from $6.3 billion today. Simply Wall St community members have only three fair value estimates for AbbVie, ranging from about US$273 to US$455 per share, showing very different expectations.